Results 151 to 160 of about 4,863 (192)

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management. [PDF]

Blood Cancer J
Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA, Nedved AN, Durani U, Iqbal M, Wang Y, Paludo J, Villasboas JC, Dingli D, Kourelis T, Leung N, Alkhateeb H, Ruff MW, Gallo de Moraes A, Vergidis P, Herrmann J, Kenderian SS, Bennani NN, Johnston PB, Ansell SM, Lin Y.   +24 more
europepmc   +1 more source

Unraveling the Complexities of Idiopathic Multicentric Castleman Disease and Its Multi-systemic Associations: A Case Report. [PDF]

Cureus
Palvia AR, Saha P, Nandi AR, Damera AR, Suresh A.   +4 more
europepmc   +1 more source

Targeting the JAK/STAT Signaling Pathway in Breast Cancer: Leaps and Hurdles. [PDF]

Biomedicines
Aho S, Coste C, Purcari L, Trédan O, Poulard C, Mery B, Boisvert FM, Le Romancer M.   +7 more
europepmc   +1 more source

TAFRO subtype of idiopathic multicentric Castleman disease in a 22-year-old man. [PDF]

CMAJ
Rowe S, Collins BW, Pirzada A, Manning N, Chen LYC.   +4 more
europepmc   +1 more source

Immunotherapy plus Chemotherapy for Patients with EGFR-Mutated Non-Squamous Cell Lung Cancer for Disease Progression after EGFR Tyrosine-Kinase Inhibitor: A Meta-Analysis of Randomized Controlled Trials.

Oncology
Refae AA, Abu Shakra RI, Ibrahim EM.
europepmc   +1 more source

Corrigendum: Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences. [PDF]

Drugs Context
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical Development of Siltuximab

Current Oncology Reports, 2015
Siltuximab is a chimeric monoclonal antibody targeting interleukin-6 (IL-6), which in the fall of 2014 became the first FDA-approved treatment of the rare disease idiopathic multicentric Castleman's disease (MCD). MCD is a non-clonal lymphoproliferative disorder in which common symptoms include fever, night sweats, weight loss, and fatigue.
Christine C, Davis, Katherine S, Shah, Mary Jo, Lechowicz   +2 more
openaire   +2 more sources

Siltuximab: First Global Approval

Drugs, 2014
The anti-interleukin-6 (IL-6) chimeric monoclonal antibody siltuximab is the first drug to be approved for the treatment of multicentric Castleman's disease (MCD) in the US and European union (EU), having gained approval under the FDA priority review program in the US and from an accelerated assessment and recommendation by the Committee for Medicinal ...
Anthony, Markham, Trina, Patel
openaire   +2 more sources